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Alzheimer’s disease (AD), a primary cause of dementia in the aging population, is
characterized by extracellular amyloid-beta peptides aggregation, intracellular deposits
of hyperphosphorylated tau, neurodegeneration and glial activation in the brain. It is
commonly thought that the lack of early diagnostic criteria is among the main causes
of pharmacological therapy and clinical trials failure; therefore, the actual challenge is
to define new biomarkers and non-invasive technologies to measure neuropathological
changes in vivo at pre-symptomatic stages. Recent evidences obtained from human
samples and mouse models indicate the possibility to detect protein aggregates and
other pathological features in the retina, paving the road for non-invasive rapid detection
of AD biomarkers. Here, we report the presence of amyloid beta plaques, tau tangles,
neurodegeneration and detrimental astrocyte and microglia activation according to a
disease associated microglia phenotype (DAM). Thus, we propose the human retina
as a useful site for the detection of cellular and molecular changes associated with
Alzheimer’s disease.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder leading to dementia during elderly. This
pathology is manifested with cognitive and psychiatric symptoms such as memory and cognitive
impairments, behavioral abnormalities, disorientation and circadian rhythms disturbances (Hart
et al., 2016). Due to population aging, AD cases are constantly increasing and it is estimated
that by the year 2050 AD will globally affects about 115 million people (Alzheimer’s Disease
International World Alzheimer Report, 2009; Scheltens et al., 2016) thus posing a growing concern
on public health.
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Studies from post-mortem brains revealed that, at the
neuropathological level, distinctive features of AD include
aggregation of amyloid beta protein (Aβ) and tau protein
hyperphosphorylation (pTau), which cause synapses loss and
neuronal degeneration. These plaques and tangles are generally
associated with activated microglia and reactive astrocytes in AD
brain (Ahmed et al., 2017; Henstridge et al., 2019). Over the years
several candidate drugs have been proposed as a putative therapy
for AD. However, despite many attempts, a definitive cure has not
been found yet and only symptomatic treatments are available.
A possible explanation for this arises from the fact that
AD is a complex multifactorial disorder, while pharmacological
treatments are preferentially directed against a specific cellular
target. Moreover, proteins aggregation can occur decades
before the appearance of neurological symptoms, thus making
interventions at later stages less effective.
It is therefore tempting to speculate that AD diagnosis at
earlier stages, possibly when synapses and neuronal functions
are not yet compromised, could give better results in terms of
pharmacological and clinical intervention (Frisoni et al., 2017).
The search for early biomarkers in AD has become a
very attractive area of study. Imaging brain changes in Aβ
with techniques such as computed tomography (CT), magnetic
resonance index (MRI) and positron emission tomography (PET)
in combination with the analysis of cerebrospinal fluid (CSF)
have established Aβ and tau as an indicator of the AD disease.
In particular, both PET and CSF biomarkers allow to diagnose
AD during the prodromal phase of the disease (Rowe et al.,
2013; Petersen et al., 2016), but pitfalls such as high cost
and invasiveness make these tests unsuitable for a population-
wide screening.
Recently, researchers focused their interests on the retina in
order to find new biomarkers for AD. The rationale behind
this choice rely on the fact that, the retina and the brain
share a common embryological origin therefore they could
share pathological mechanisms as well (Sernagor et al., 2001;
Kavcic et al., 2011; Chang et al., 2014; Lee et al., 2014; Bambo
et al., 2015; Javaid et al., 2016). Recent studies have shown
that anatomical alterations such as thinning of the ganglion
cell and retinal nerve fiber layers can be detected already
during AD early stages (Thomson et al., 2005; Paquet et al.,
2007) thus strengthening the idea that the retina could be
used in early AD diagnosis. However, far from reaching a
consensus, studies on retinal tissues from AD patients and mouse
models produced contrasting results. For instance, amyloid
plaques have been found in AD post-mortem retinas (but
not in control cases) by Löffler et al. (1995). Similar results
have been confirmed by other research groups (Hoh Kam
et al., 2010; Alexandrov et al., 2011; Koronyo-Hamaoui et al.,
2011; Koronyo et al., 2017), in addition a positive correlation
between inclusion body and cortical amyloid burden has been
observed (Snyder et al., 2016). On the contrary, den Haan and
collegues detected a signal for phosphorilated Tau (pTau) in the
inner and outer plexiform layer of the retina (IPL and OPL
respectively), but they did not find any signal for Aβ plaques
and neurofibrilary tangles (den Haan et al., 2018). Most likely,
these discrepancies may be attributed to differences in staining
methods, sections preparation and time of tissue harvesting.
Moreover, restricting retinal analysis to the presence of protein
aggregates and vascular alterations solely may be poorly specific
for AD diagnosis, as Aβ deposits have been found also in
other pathological conditions such as macular degeneration
(Zhao et al., 2015). Beyond classical neuropathological hallmarks,
proteomic analysis of cerebrospinal fluid from AD patients
revealed the upregulation of proteins related to microglia and
astrocytes activation. For instance, Aβ plaques aggregation can
activate astrocytes and microglia thus inducing the release of
mediators of inflammation such as interleukin-1 beta (IL-1β)
and ultimately cellular and neuronal apoptosis both in brain and
retina (Liu et al., 2014).
In neurodegenerative disease, microglia response consists in
migrating to sites of damage or injury, secreting numerous
inflammatory molecules, and phagocytizing debris and
aggregated proteins (Heneka et al., 2015; Song and Colonna,
2018). However, microglia, astrocytes and immune signaling
are not just secondary players in disease processes but actually
contribute to synaptic and neuron loss and buildup of pathogenic
proteins even at the earliest stages of disease (Hong et al., 2016;
Shi et al., 2017; Sosna et al., 2018). Aggregation of Aβ plaques
can lead to inflammatory reactions, astrocytes and microglia
activation, release of inflammatory cytokines such as interleukin-
1 beta (IL-1β) and cellular and neuronal apoptosis in both the
brain and retina (Liu et al., 2014). Moreover, the misregulated
expression of glia released soluble factors in AD has been linked
to disease associated microglia, and to microglia induced NLRP3
inflammasome and complement activation (Heneka et al., 2013;
Sheedy et al., 2013; Lian et al., 2015; Iram et al., 2016) and
synaptic loss (Hong et al., 2016). Moreover, a specific microglia
phenotype has been described in neurodegenerative diseases
characterized by the downregulation of microglia homeostatic
genes, the upregulation of specific degeneration associated
markers (DAM), and sustained by the upregulation of TREM2
(Yeh et al., 2017; Deczkowska et al., 2018).
To gain a better understanding and to identify new molecular
targets for a more complete panel of putative biomarkers
for AD diagnosis, we performed immunostaining on human
retinas obtained from both AD patients and age matched
controls. We report the presence of Aβ and pTau protein
aggregates together with neuronal loss. We also report, for
the first time, the upregulation of IL1-β on microglia and the
presence of neurotoxic A1 astrocytes in AD retina. These findings
highlight protein aggregates and cellular markers as targets to be
considered for AD diagnosis.
MATERIALS AND METHODS
Human Samples
Human retinal slices from AD patients and age matched controls
were purchased from Human Eye Biobank for Research, St
Michael Hospital, Toronto, Canada. Prior to death, donors signed
informed consent for autopsy and use of tissue and medical
records for research purposes. No documented history of eye
disease was reported for the AD or control cases. The use of
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human tissue has been approved by the Ethics Committee of
Fondazione Santa Lucia I.R.C.C.S. to GR.
Immunofluorescence
Slices were deparaffined with absolute Xylene (3 × 5 min)
and rehydrated by scaling down from 100% to 50% ethanol,
2× 10 min for each concentration. After PBS washes (3× 5 min),
antigen retrieval has been performed by soaking slices for 40 min
in a warm solution containing (in mM): 10 Na-citrate, 0.05%
Tween 20, pH 6.0, 90◦C. Subsequently, slices were incubated for
45 min in a blocking solution (3% goat serum and 0.3% Triton
X-100 in PBS). Primary antibodies diluted in blocking solution
were incubated over-night at 4◦ [anti-βTubulin III, T2200,
Sigma, clone Aa441-450, 1:500; anti-GFAP, MAB360, Millipore,
clone GA5; 1:400; anti-Iba1, 019-19741, Wako, 1:400; anti-
OPN, 691302, Biolegend, clone A15059B, 1:100; Anti-βAmyloid,
8243s, CELL SIGNALING, clone D54D2, 1:100; anti-Cleaved-
Casapase3, 9661s, CELL SIGNALING, clone Asp175, 1:100; anti-
PhosphoTau (Thr212, Ser214), MN106, INVITROGEN clone
AT100 1:50; anti-PhosphoTau (Ser 202, Thr205), INVITROGEN,
clone AT8, 1:40; anti-C3d, A0063, Dako, 1:500; anti-IL-1β,
sc-32294, Santa Cruz Biotechnology, clone E7-2-hIL1β, 1:50].
After three washes in PBS, sections were stained for 45 min
with a secondary antibody and Hoechst in order to visualize
nuclei, then coverslips were mounted with Diamond Antifade
Mountant (Molecular Probes) and images acquired with a
confocal microscopy.
Confocal Spinning Disk and VCS
Microscopy
The acquisition of the images was performed through a
Nikon Eclipse Ti equipped with a X-Light V2 spinning disk
combined with a VCS (Video Confocal Super resolution) module
(CrestOptics) based on structured illumination and with a LDI
laser source (89 North). The images were acquired by using
Metamorph software version 7.10.2. (Molecular Devices) with
a 60x PlanApo λ oil objective (1.4 numerical aperture) and
sectioning the slice in Z with a step size of 0.2 µm for spinning
disk and 0.15 µm for VCS to obtain a total Z-stack of about
10µm. In order to achieve super-resolution, raw data obtained by
the VCS module have been processed with a modified version of
the joint Richardson-Lucy (jRL) algorithm (Ingaramo et al., 2014;
Ströhl and Kaminski, 2015; Chakrova et al., 2016), where the
out of focus contribution of the signal has been explicitly added
in the image formation model used in the jRL algorithm, and
evaluated as a pixel-wise linear “scaled subtraction” (Heintzmann
and Benedetti, 2006) of the raw signal. The acquisitions obtained
were transformed into a z-projection and then analyzed using the
ImageJ software.
Laser Scanning Acquisitions
For conventional confocal laser scanning analysis of retinal slices,
images acquisition has been performed through a confocal laser
scanning microscope (microscope (FV10i Olympus) equipped
with a 60x water immersion objective. Acquired images were
processed and analyzed off line using ImageJ. For each retina six
images were acquired. For every image the maximum intensity
projections of z-series stacks was created.
Microglia Density Analysis
The number of Iba1+ microglia cells has been reported as
number of somas per acquired area (400 µm2). To quantify
microglia density, the same images were analyzed by Metamorph
software. A z-projection based on the maximal intensity signal
was obtained and after threshold setting, fluorescence intensity
value has been recorded. Data are expressed as area occupied by
fluorescent cells versus total slice area.
Astrogliosis Analysis
Astrogliosis analysis has been performed by staining retinas
section for GFAP and C3. Following threshold adjustment
astrogliosis was quantified as fluorescence intensity above
threshold. Data are expressed as area occupied by fluorescent
cells versus total slice area. For the measurement of GFAP/C3
colocalization, the value of GFAP-overlapping the C3
signal was considered.
Analysis of Neurodegeneration
Confocal images of cells positive for cleaved caspase 3, an effector
enzyme of the apoptotic pathway, were analyzed by means of
Metamorph software. We manually counted the number of cells
positive for the signal of the cleaved caspase 3 within each
image. Thereafter, this number has been divided by the total
number of ganglion neurons counted in the region of interest
(ROI) and thus expressed as percentage of degenerating ganglion
cells in each slice.
FISH
Sections were deparaffined with absolute Xylene (3× 5 min) and
partially rehydrated with 70% ethanol (2 × 10 min each) before
proceeding with RNA FISH staining. RNA in situ hybridization
was performed as described previously (Raj and Tyagi, 2010)
with minor modifications: briefly, sections were incubated in
Wash Buffer A (Stellaris, Biosearch Technologies) for 5 min and
then, in the Hybridization Buffer supplemented with 2 mM VRC
complex (Sigma, R3380) and 125 nM TREM2 FISH probes 3′-end
labeled with Quasar 670 fluorophore (Biosearch Technologies,
SMF-1063-5). Incubation was performed overnight at 37◦C
in Top Brite automatic slide hybridizer (Resnova). After two
washes in Wash buffer A for 30 min and one wash with Wash
Buffer B for 5 min at 37◦C, Hoechst was added for 15 min at
room temperature. Finally, slices were mounted with ProLong
Diamond Antifade Mountant (Thermo Fischer Scientific P-
m36961) and analyzed with a confocal laser scanning microscope.
Immunofluorescence for IBA1 was performed sequentially to
RNA FISH staining.
Protein Aggregates
The size of the amyloid plaques and tau tangles was studied on
images acquired with the confocal microscope and subsequently
analyzed with the Metamorph program (version 7.6.5.0). The
“Trace Region” function of this program makes it possible to
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surround the deposits of these proteins and to obtain their
volume expressed in µm3. Their density has been studied with
the ImageJ program through which it was possible to count the
number of these aggregates within each slice analyzed.
Statistics and Data Analysis
Data are shown as the Mean ± SEM. Statistical significance
between controls and AD patients was assessed with the non-
parametric Mann–Whitney test or T-test as indicated. A p-
value < 0.05 was considered significant. All statistical analyses
were done using Sigma Plot 11.0, Origin or Clampfit software.
RESULTS
Typical Aβ and pTau Protein Aggregates
in AD Human Retina
The accumulation of Aβ and pTau aggregates in the retinal tissue
has been reported on both AD human tissue (Koronyo-Hamaoui
et al., 2011; Koronyo et al., 2017) and mouse models (Criscuolo
et al., 2018; Grimaldi et al., 2018), thus suggesting a putative use
of the eye as a valuable structure for the study and the diagnosis
of AD and other neurodegenerative disease. However, due to the
complex nature of the disease, and to the positive Aβ staining in
macular degeneration (Lynn et al., 2017), a more comprehensive
panel of biomarkers needs to be defined to avoid misleading
AD diagnosis. Using human retinal slices from AD patients and
controls (samples were obtained from the St. Michael’s Hospital
Human Eye Biobank), we first confirmed the presence of Aβ and
pTau aggregates in the retinal layers.
We analyzed retinal cross sections from 10 clinically and
neuropathologically confirmed AD patients (mean age ± SEM:
85.7± 2.7 years; range 71–98 years; 8 females and 2 males) and 10
healthy controls (mean age ± SEM: 75.3 ± 2.9 years; range: 65–
93 years; 6 females and 4 male). In all AD patients we detected
retinal Aβ immunoreactivity and deposits both in the inner
and outer layers (minimum diameter: 110 nm; Figures 1A,B).
Aβ staining, evaluated as Aβ plaques number in a region of
400 µm2, was significantly higher in AD patients (10.4 ± 1.8
n = 45/5 fields/patients) compared to controls (3.8± 0.7 n = 44/5
fields/controls; p< 0.01; Figure 1C). Sparse and diffuse retinal Aβ
deposits were found occasionally also in control slices (Figure 1A,
left), as previously reported (Koronyo et al., 2017). Plaques
volume measured on 3D stacks was higher in AD patients respect
to controls as reported in the histogram in Figure 1D.
In order to assess the presence of hyperphosphorylated
tau isoforms we performed immunofluorescence analysis using
two different monoclonal antibodies directed against the
hyperphosphorylated tau protein (pTau; clone AT-8 and clone
AT-100, Figure 1E). Following the staining with the AT-100 clone
we observed a strong and diffuse staining for pTau both in the
IPL and OPL in the majority of AD patients (6/10). Indeed,
pTau immunoreactivity was significantly higher in the AD retina
compared to age matched controls as quantified by fluorescence
intensity in each field of view (AD: 0.76 ± 0.11, n = 38/6
fields/patients; CTRL: 0.22 ± 0.06, n = 32/6 fields/controls;
p < 0.005; FOV = 400 µm2; Figure 1F), thus confirming the
accumulation of neurofibrillary tangles deposits in AD patients
retina (Figure 1E, right). Using the AT-8 clone we found discrete
pTau immunofluorescence in the IPL and in the OPL only in
two out of 10 patients analyzed; in these AD patients the number
of pTau tangles was significantly higher respect to control (AD:
4.4 ± 1.7, n = 15/2 fields/patients; CTRL: 0.9 ± 0.4; n = 15/2
fields/controls; p < 0.05; not shown). Co-labeling the retina with
AT-100 and TUJ1 as neuronal marker indicated that in AD retina
pTau expression was mainly in the Retinal Ganglion Cells (RGC)
of the inner layer (IL; Figure 1G).
These findings clearly demonstrate an increase in Aβ and pTau
aggregates in the retina of AD patients respect to controls thus
pointing at them as putative biomarkers for AD diagnosis.
AD Human Retina Displays
Neurodegeneration in the Ganglion Cell
Layer
An increased cleavage of proteins such as APP and
presenilins operated by caspase-3, has been associated with
neurodegeneration in AD (Louneva et al., 2008). In a previous
paper from our laboratory, we reported immunoreactivity for the
cleaved caspase-3 at the level of the RGC layer of the 3xTg-AD
mouse model (Grimaldi et al., 2018). A positive staining for
caspase-3 is also present in the IL of human retinas (Figure 2A,
green dots) in TUJ1 positive cells (red). In particular we found
that the number of caspase-3 positive retinal ganglion cells in
each field of view (FOV) examined was increased compared to
age matched controls (AD: 11.4 ± 2.2%, n = 17/6 fields/patients;
CTRL: 6.0 ± 1.0%, n = 18/6 fields/control; p < 0.05; Figure 2B)
These results indicated that the AD retinal IL is more subject
to neuronal death thus suggesting that visual defects and optic
nerve thinning observed in AD may rely on retinal ganglion cells
neurodegeneration.
Increased Astrocytosis and Microglia
Reactivity in AD Patients Retina
In AD brain, astrocytes have been found closely associated with
fibrillar amyloid plaques suggesting that Aβ accumulation may
serves as a cue for the activation of this cell type (Henstridge et al.,
2019). Astrocytes activation can have a neuroprotective effect
but it may trigger the release of pro-inflammatory species such
as cytokines and chemokines (Stadelmann et al., 2002; Farina
et al., 2007). To evaluate putative astrogliosis in the retina of AD
patients we performed immunostaining for the GFAP. Analysis
of acquired images showed a marked astrogliosis localized at the
level of the ganglion cell layer. Astrogliosis may arise also as a
consequence of aging however, the amount of astrocyte activation
was more pronounced in the AD retina compared to controls
(Figure 3A), as quantified by fluorescence intensity in each field
of view (AD: 5.5 ± 1.1, n = 44/6 fields/patients; CTRL: 1.9 ± 0.3,
n = 44/6 fields/controls; p< 0.001; Figure 3B).
As for astrocytes, also microglia activation can show a dual
role in inflammatory processes. Increased microglia reactivity
in the retina has been observed in post-mortem tissues from
AD patients (Beach et al., 1989) and in the 3xTg-AD mouse
model (Grimaldi et al., 2018). Immunostaining against Iba1 a
Frontiers in Neuroscience | www.frontiersin.org 4 September 2019 | Volume 13 | Article 925
fnins-13-00925 August 31, 2019 Time: 18:20 # 5
Grimaldi et al. Retinal Biomarkers for Alzheimer’s Disease
FIGURE 1 | Human AD retina displays β-amyloid and pTau aggregates. (A) Representative images of retinal slices from AD patients and control cases
immunolabeled with anti-β-amyloid antibody (green) and Hoechst for nuclei visualization (blue); bar 20 µm. (B) Insert representing β-amyloid staining in AD retina at
higher magnification; bar 20 µm (C) Number of β-amyloid plaques/field of view (∗∗p < 0.01 AD vs. Ctrl; t-test; n = 45/5 fields/patients). (D) Distribution of β-amyloid
plaque volume measured in AD patients and control cases. (E) Representative images of retinal slices from AD patients and control cases immunolabeled with
anti-p-tau AT-100 antibody (green) and Hoechst for nuclei visualization (blue); bar 20 µm. (F) Quantification of p-tau AT-100 area covered by fluorescent signal/field of
view (∗∗∗p < 0.001 AD vs. Ctrl; t-test; n = 38/6 fields/patients). (G) Representative images of retinal slices from AD patients and control immunolabeled with
anti-p-tau AT-100 (green) and anti-TUJ1 as RGC marker (red) at higher magnification (Hoechst for nuclei visualization in blue; bar 20 µm). IL, inner layer; OL, outer
layer.
FIGURE 2 | Ganglion cell neuron degeneration in AD patient’s retina. (A) Representative images of retinal slices from AD patients and control cases immunolabeled
with anti-cleaved caspase-3 antibody (green), anti-TUJ1 as RGC marker (red) and Hoechst for nuclei visualization (blue); bar 20 µm. (B) Bar chart representing the
percentage of RGC neuron positive for cleaved caspase-3 on each field of view (∗p < 0.05 AD vs. Ctrl; t-test; n = 17/4 fields/patients). IL, inner layer; OL, outer layer.
microglia marker, revealed that this cell type was mainly present
in two layers: the inner plexiform and the outer plexiform
layers (Figure 3C). Microglia cell density was increased in
AD patients retina compared to age matched controls (AD:
3.9 ± 0.3; n = 73/10 fields/patients; CTRL: 2.5 ± 0.3, n = 73/10
fields/controls; p< 0.005; Figure 3D).
These results, confirming the presence of altered astrocyte and
microglia density in human AD retina, suggest the possibility to
add markers for glial activation in the set of retinal biomarkers
for AD diagnosis.
AD Human Retina Displays Upregulation
of Neurotoxic Microglia and Astrocytes
Several different proteins have been demonstrated to be involved
in the interplay among neurons, astrocytes and microglia in
neurodegenerative diseases. Particularly, altered expression of
these proteins in AD has been linked to disease associated
microglia, to microglia induced detrimental astrocytes activation
(Heneka et al., 2013; Sheedy et al., 2013) and synaptic loss (Hong
et al., 2016). Here we examined and compared the expression
of IL-1β, TREM-2 (triggering receptor expressed on myeloid
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FIGURE 3 | Increased astrocytes and microglia cell density in the retina of AD
patients. (A) Representative images of retinal slices from AD patients and
control cases immunolabeled with anti-GFAP antibody (red) and Hoechst for
nuclei visualization (blue); bar 20 µm. (B) Quantification of GFAP area covered
by fluorescent signal/field of view (∗∗∗∗p < 0.001 AD vs. Ctrl; t-test; n = 44/6
fields/patients). (C) Representative images of retinal slices from AD patients
and control cases immunolabeled with anti-Iba1 antibody (red) and Hoechst
for nuclei visualization (blue); bar 20 µm. (D) Quantification of Iba1 area
covered by fluorescent signal/field of view (∗∗∗p < 0.005 AD vs. Ctrl; t-test;
n = 73/10 fields/patients). IL, inner layer; OL, outer layer.
cells-2), complement component C3 and OPN (Osteopontin)
between AD and control samples.
Immunofluorescence analysis of IL-1β expression on AD
retinal slices showed enhanced IL-1β cytoplasmic staining in
the inner nuclear layer (INL) of AD patients compared to age
matched controls (Figure 4A, left). IL-1β immunostaining in AD
patients retina was found to be colocalized with Iba1-expressing
cells, a marker of microglia, but not with the astrocytes marker
GFAP (not shown). Indeed, co-labeling with Iba1 (Figure 4A,
right) revealed that the number of microglia cells positive for IL-
1β was significantly higher compared to control (AD: 3.5 ± 0.4,
n = 31/5 fields/patients; CTRL: 2.2± 0.4, n = 29/5 fields/controls;
p < 0.05; Figure 4B; average number of Iba1/IL-1β + cells
for each FOV), with almost all microglia cells expressing IL-
1β in AD.
Astrocytic C3 upregulation has been demonstrated to be
downstream of the microglia induced IL1-β activation. Moreover,
its expression seems to be regulated by β-amyloid in both
AD mouse models and human brain (Lian et al., 2015).
C3 upregulation is now considered to be a marker for
detrimental A1 astrocytic phenotype taking part in AD related
synaptic loss. We examined C3 expression in human retina by
immunofluorescence analysis. We found C3 to be expressed
in the ganglion cell layer. Co-staining with GFAP revealed
that C3 immunoreactivity was confined in GFAP positive cells
as shown in Figure 4C. Fluorescence intensity quantification
showed that the percentage of C3 positive astrocytes was strongly
upregulated in AD retina respect to control (AD: 26 ± 4,
n = 45/6 fields/patients; CTRL: 7.8± 1.6, n = 46/6 fields/controls;
p< 0.001; Figure 4D).
Upregulation of OPN in AD patients CSF may arise from
neurons, microglia or both. Indeed, while the OPN encoding
gene SPP1 (secreted phosphoprotein 1) is now considered a
good DAM microglia marker (Ulland et al., 2017), AD brains
display OPN upregulation in CA1 pyramidal neurons (Wung
et al., 2007). We analyzed the expression level of OPN in
human retinal slices of AD patients and age matched controls
by immunofluorescence analysis using a monoclonal antibody
against the full length OPN peptide (Figure 5A, left). We
found significant upregulation of OPN expression in AD retinas,
quantified as fluorescence intensity over threshold in each field
of view (400 µm2) (AD: 3.0 ± 0.6, n = 24/3 fields/patients)
compared to age matched controls (CTRL: 0.7 ± 0.2, n = 27/4
fields/patients; p < 0.001) (Figure 5B). OPN expression was
localized in the retinal ganglion cell layer as demonstrated by
the co-staining against tubulin isoform βIII (TUJ1; Figure 5A,
middle), a selective marker for RGC neurons. Indeed, the
percentage of RGC neurons positive for OPN (Figure 5A, left)
was significantly higher in AD respect to control retinas (AD:
84 ± 5%, n = 36/6 fields/patients; CTRL: 63 ± 6%, n = 34/6
fields/patients; p< 0.01; Figure 5C). Conversely, co-labeling with
anti-Iba1 did not show upregulated OPN expression on microglia
(data not shown).
TREM2 is now considered a crucial regulator in promoting
microglia responses to Aβ in AD. TREM2 transcript has been
shown to be over-expressed by microglia both in the brain of
AD mouse models as well as human patients (Frank et al., 2008;
Lue et al., 2015; Wang et al., 2015), suggesting that TREM2 up-
regulation could mirror with AD progression. Moreover, in the
3xTg-AD mouse model, we reported the upregulation of TREM2
mRNA in sorted retinal microglia cells (Grimaldi et al., 2018).
Due to the lack of specific antibodies against human TREM2,
FISH experiments have been performed in order to evaluate the
expression level of TREM2 transcript in retinal slices of AD
patients and age matched controls (Figure 5D). The analysis
of TREM2 RNA levels obtained with fluorescence threshold
analysis did not show, on average, any difference between AD and
control retinas (AD: 0.18 ± 0.03, n = 31/4 fields/patients; CTRL:
0.22 ± 0.06, n = 37/4 fields/controls; p = 0.3; data not shown).
However, the number of TREM2 positive cells in each field of
view (400 µm2) was higher in AD retina respect to control (AD:
8.5 ± 0.8, n = 31/4 fields/patients; CTRL: 6.2 ± 0.6, n = 37/4
fields/controls; p < 0.05; Figure 5E), indicating an increased
TREM-2 expression. When TREM2 FISH analysis was performed
together with immunofluorescence for Iba1, we observed Iba1
positive cells expressing TREM2 in AD retina (Figure 5D, left).
It should be noticed, however, that in our experiments TREM2
staining was not exclusively confined to Iba1-positive cells. This
could be ascribed to protein denaturation taking place during
FISH protocol, preventing an absolute quantification of TREM2
expressing retinal microglia cells.
These data indicate that detrimental astrocytic and microglia
activation can be detected in AD patients retina with increased
release of pro-inflammatory compounds that could be considered
as possible biomarkers for AD diagnosis.
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FIGURE 4 | AD patient’s retina display complement C3 and IL-1β upregulation. (A) Representative images of retinal slices from AD patients (bottom) and control
cases (top) immunolabeled with anti-IL-1β antibody (green), Iba1 (red) and Hoechst for nuclei visualization (blue); bar 20 µm. (B) Quantification of cells positive for
both Iba1 and IL-1β signal/field of view (∗p < 0.05 AD vs. Ctrl; t-test; n = 31/5 fields/patients). (C) Representative images of retinal slices from AD patients and
control cases immunolabeled with anti-GFAP antibody (red), C3 (green) and Hoechst for nuclei visualization (blue); bar 20 µm. (D) Quantification of GFAP/C3
co-localization area/field of view (∗∗∗∗p < 0.001 AD vs. Ctrl; t-test; n = 45/6 fields/patients). IL, inner layer; OL, outer layer.
DISCUSSION
As of now, a definitive AD diagnosis is made possible only
after post-mortem examination of brain tissue (Elahi and Miller,
2017). Despite many attempts there is an urgent need to find new
easy-to-acquire, cost-effective strategies for AD diagnosis, even
at early stages in order to allow a timely and effective therapeutic
program (Frisoni et al., 2017).
The retinal tissue is now considered as a very promising
structure to be used in searching of new AD biomarkers as it is
thought that it could mirror the pathological changes happening
in the brain during the disease progression. Even more, the retina
is an accessible structure and this anatomical feature could be of
extreme importance in the development of new imaging methods
for its examination.
However, Aβ and pTau protein aggregates could not
be considered specific markers to AD therefore, a more
comprehensive panel of biomarkers is needed.
For this reason, we used post-mortem retinal slices from
AD patients to investigate the presence of classical AD features
and the expression of specific neuron-to-glia signaling proteins
found both in the CSF of AD patients and in the brain of AD
mouse models (Doens and Fernández, 2014). We here report
that AD patients retina show, in addition to the presence of
Aβ plaques and pTau tangles, ganglion neuron degeneration,
astrogliosis, microglia activation, and up-regulation of specific
disease associated neuron-to-glia signaling proteins, such as IL-
1β, C3, OPN and TREM2.
In agreement with previous results (Koronyo et al., 2017;
den Haan et al., 2018), we observed increased Aβ deposits and
diffuse spreading of pTAu signals in the inner retinal layer of AD
patients compared to age-matched controls. However, it has to
be noticed that only a subset of AD retinal slices here analyzed
were positive for pTau staining with AT-8 and AT-100 antibodies,
this could be ascribed to pTau specific topographic distribution
in human retina; indeed pTau staining was clearly reported in the
anterior part of the superior retina (Koronyo et al., 2017; den
Haan et al., 2018), and using transverse retinal slices obtained
from the Human Eye Bank we could not asses which part of
the retina we were analyzing. Due to this technical issue it is
plausible that we are underestimating the amount of pTau in
the AD patients retina. Also, we show that neuronal apoptosis is
significantly higher in the retina of AD patients compared to age
matched controls, predominantly in RGC layer.
As it is well known that glial cells are activated in AD
associated inflammatory states, we performed immunostaining to
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FIGURE 5 | Osteopontin and TREM2 expression in AD patient’s retina. (A) Representative images of retinal slices from AD patients (bottom) and control cases (top)
immunolabeled with anti-OPN (green), tuj-1 (red) and Hoechst for nuclei visualization (blue); bar 20 µm. (B) Quantification of OPN area covered by fluorescent
signal/field of view (∗∗∗∗p < 0.001 AD vs. Ctrl; t-test; n = 24/3 fields/patients). (C) Quantification of OPN/TUJ1 co-localization area/field of view, in% (∗∗p < 0.01 AD
vs. Ctrl; t-test; n = 36/6 fields/patients). (D) Representative images of retinal slices from AD patients (bottom) and control cases (top) stained with anti TREM2 mRNA
fluorescent probe (red), anti-Iba1 (green) and Hoechst for nuclei visualization (blue); bar 20 µm. Note that cells expressing TREM2 are not always positive for Iba1.
(E) Number of TREM2 positive cells/field of view (∗p < 0.05 AD vs. Ctrl; t-test; n = 31/4 fields/patients). IL, inner layer; OL, outer layer.
evaluate putative difference between controls and AD samples.
Although GFAP and Iba1 reactivity was present both in AD
and aged controls, the area of GFAP positive staining and
the number of microglia cells were significantly higher in AD
retinas thus indicating that glia (both astrocytes and microglia)
activation is significantly more pronounced in AD retinas
compared to controls.
We show here for the first time that retinal microglia of AD
patients display, respect to their age matched controls, higher
expression of IL-1β a typical marker of pro-inflammatory and
DAM microglia (Keren-Shaul et al., 2017) suggesting microglia
response to Aβ and pTau accumulation. These results are in line
with the increased expression of IL-1β found in brain microglia
in human patients and mouse models (as reviewed in Shaftel
et al., 2008). Conversely, while in the brain of 5xFAD mouse
model IL-1β was overexpressed by astrocytes (Rosenzweig et al.,
2019), in human AD and control retina we did not observe IL-
1β expression in GFAP positive cells. It should be noted that we
found enhanced IL-1β staining also in other cells in the INL of
AD retina, probably due to the NLRP3 inflammasome activation
and monocytes infiltration.
We also report an increase of TREM2 mRNA level in the
retina of AD patients respect to aged controls. The importance
of TREM2 in the central nervous system (CNS) is widely
recognized, as TREM2 mutations are linked to an increased
risk of developing several neurodegenerative diseases (Ulland
and Colonna, 2018), and TREM2 RNA has been found to
be upregulated in the brain of patients and mouse models
(Keren-Shaul et al., 2017). Moreover, we previously reported
TREM2 upregulation in retinal microglia sorted from early
symptomatic 3xTg-AD mice (Grimaldi et al., 2018). However,
while it is evident that TREM2 expression on microglia cells
plays a prominent role in driving microgliosis in the brain
of AD mouse models and patients (Keren-Shaul et al., 2017),
we did not find increased expression of TREM2 transcript
on Iba1 positive cells in the retina of AD patients. It can
be speculated that in our samples the expression of TREM2
on microglia cells is underestimated due to technical reasons.
Indeed, RNA FISH experiments on post-mortem paraffin-
embedded tissue is per se technically challenging, requiring
the use of formamide to increase the hybridization efficiency
(Cattoretti et al., 1993; Gilbert et al., 2007). This procedure might
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induce protein denaturation causing the failure of subsequent
immunofluorescence analysis. Another possible explanation may
rely on the age of AD patients here analyzed. Indeed, while
microglia TREM2 expression is important in triggering and
sustaining the DAM phenotype in response to protein aggregates
during disease progression (Song and Colonna, 2018; Ulland and
Colonna, 2018), downregulation of TREM2 has been reported
in human post-mortem retinal tissues of patients suffering from
Age-Related Macular Degeneration (Bhattacharjee et al., 2016)
where Aβ deposits are present. In this framework it is likely
that post mortem retinal tissue from aged patients is not the
ideal specimen for TREM2 analysis. Moreover, the observed
increase in TREM2 transcript level could be due to infiltrating
monocytes negative for Iba1, as reported in the brain of AD
patients (Fahrenhold et al., 2018).
The analysis of osteopontin expression in retinal tissue
revealed increased OPN staining in AD retinal ganglion cells
with evident colocalization with tubulin β-III. This result is
partially in contrast with previous findings in the AD brain.
Indeed, although OPN transcript (SPP1) expression has been
shown to be upregulated in microglia in AD models (Ulland
et al., 2017) and thus considered a marker for DAM phenotype,
we did not find OPN upregulation on Iba1 positive cells. On
the other hand our result is in line with data reporting that
the protein osteopontin is upregulated on CA1 hippocampal
pyramidal neurons in human AD brain (Wung et al., 2007).
Moreover, in mouse retina, OPN is reported to be expressed on
RGC (Ju et al., 2000; Duan et al., 2015). These considerations
make OPN a good candidate biomarker for retinal AD diagnosis
despite its cellular localization.
Here, for the first time we report the presence of A1 astrocytic
phenotype in the retina of AD patients, as revealed by the strong
upregulation of C3 protein on retinal astrocytes. This result
is consistent with the reported presence of A1 reactive brain
astrocytes in neurodegenerative diseases (Liddelow et al., 2017).
The importance of reactive A1 astrocytes in neurodegenerative
diseases rely on the evidence that synaptic loss can be favored by
element of the complement cascade released by the A1 astrocytes
(Stevens et al., 2007; Hong et al., 2016; Sekar et al., 2016). It
is noteworthy that A1 activation may be initiated by microglia
released IL-1β as well as by extracellular Aβ accumulation (Lian
et al., 2015; Liddelow and Barres, 2017), both found and here
reported in retina of AD patients.
These observations further support the possibility that ocular
biomarkers could be used for early detection of AD associated
neurodegeneration. It should be noted, however, that other ocular
pathologies, such as glaucoma shares histopathological hallmarks
with AD including increased levels of tau protein and microglial
activation (Ramirez et al., 2017). It is therefore desirable that a
complete panel of biomarkers able to discriminate between age-
related and disease-related retinal changes would be available
and could be used as a target for in vivo imaging through a
retinal scan. However, this will requires the development of both
specific AD biomarkers ligands and long working distance high
resolution imaging techniques, in order to achieve a non-invasive
and inexpensive diagnosis of AD through the retinal scan.
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